Continuous xRNA Manufacturing
The Future of xRNA Manufacturing
Like many advanced and emerging modalities, xRNA therapeutics rely on traditional batch processing and offline analytics to enable each process step for an investigational drug. With funding from FDA’s Center for Biologics Evaluation and Research (CBER) Advanced Technology Program, and in partnership with MIT, Recipharm Advanced Bio has developed Recimagine™ CPS, an advanced manufacturing and analytics technology platform to match the needs of next-generation xRNA therapeutics, all in a single facility located in the heart of Boston’s biotech hub.
The Building Blocks of Accessible xRNA Therapeutics
7-14
Days
to manufacturing mRNA, rather than 3 months
While biologics account for only 2% of all prescriptions in the United States, they account for an astounding 46% of annual drug spending. While the specific numbers differ slightly in other markets worldwide, the challenge remains: The promise of advanced biologics is inaccessible to many patients due to their expense.
By combining our continually expanding knowledge hub, digital process development, continuous integrated manufacturing, and sophisticated process analytical technologies (PAT), the Recimagine™ CPS sharply decreases timelines. It runs continuously and is supported by state-of-the-art automation, significantly reducing costs and increasing advanced therapeutic accessibility.
The machine learning-enabled Knowledge Hub becomes more intelligent with every project, enabling increasingly robust predictive control and experimental knowledge
Less than 1 month rather than 6-9 months
High-throughput screening and digital simulation develop parameter targets and suggest experimental plans to optimize the recipe
7-14 days rather than 3 months
The established digital process model informs process analytics controls of the expected results at each stage. Inline analytics monitors progress, ensuring critical quality attributes (CQA) are achieved
Inline PAT capabilities and predictive analytics monitor processes in real time, eliminating the need for CQA-based gating
The Future of Advanced Therapy Manufacturing Is Fast
Recimagine™ CPS combines extensive scientific expertise, AI-enabled technologies, and state-of-the-art process analytic technologies (PAT) to reduce the finished drug product timeline by up to 67%.
Sequence to final product in less than 4 months
Consolidated xRNA Processing Solutions
Recipharm Advanced Bio provides comprehensive xRNA manufacturing solutions under one roof, including plasmid DNA and lipid nanoparticle (LNP) production.
Recipharm Advanced Bio’s flexible xRNA platform is designed to support a wide range of RNA-based therapeutics, ensuring a reliable, scalable approach from preclinical development through commercial production
Our facilities and equipment are designed for every phase of your project, scale from 1 to 50g, and utilize a range of mixing technologies
Featured Innovations & Collaborations
xRNA Manufacturing Resources
Advancing Your Program Together
Your program isn’t just another project—it’s a breakthrough in the making. At Recipharm Advanced Bio, we bring deep scientific expertise, innovative thinking, and a problem-solving mindset to every partnership. Whether scaling a complex process, navigating regulatory pathways, or optimizing for commercial success, we’re here to collaborate, adapt, and deliver with excellence.
Let’s push the boundaries of possibility together and bring transformative therapies to patients faster.